Sweden
About Swedish Orphan Biovitrum AB (publ)
Swedish Orphan Biovitrum AB (publ) is an integrated biotechnology company specializing in the research, development, manufacturing, and sale of pharmaceuticals. The company focuses on therapeutic areas such as haematology, immunology, and specialty care, serving markets across Europe, North America, the Middle East, Asia, and Australia.
Business Segments
- Haematology
- Immunology
- Specialty Care
Key Products
- Alprolix – For haemophilia B
- Aspaveli®/Empaveli – Treats paroxysmal nocturnal haemoglobinuria
- Doptelet – For thrombocytopenia
- Elocta – For haemophilia A
- Gamifant – Treats hemophagocytic lymphohistiocytosis (HLH)
- VONJO – For myelofibrosis treatment
- Zynlonta – Targets aggressive malignant diseases
- Kineret – For cryopyrin-associated periodic syndrome and Still's disease
- Orfadin – Treats hereditary tyrosinaemia type-1
- Synagis – For serious lower respiratory tract infections
Additional Offerings
The company also provides other pharmaceutical products, including:
- Akynzeo
- Tegsedi
- Jyseleca
- Kepivance
- Aloxi
- Waylivra
Research & Development
Swedish Orphan Biovitrum is actively involved in developing drug substances such as:
- ReFacto AF/Xyntha – Developed for Pfizer
- BIVV001 – For haemophilia A
- Nirsevimab – Targeting respiratory syncytial virus
Strategic Collaborations
The company has established partnerships with leading organizations, including:
- Sanofi
- Apellis Pharmaceuticals Inc.
- ADC Therapeutics SA
- Cartesian Therapeutics, Inc.
Founded: 1939
Headquarters: Solna, Sweden